European Forum for Good Clinical Practice (EFGCP), PHARMAPLEX bvba
Dr. med. Ingrid Klingmann specialized in General Medicine, Clinical Pharmacology and Pharmaceutical Medicine.
After having joined pharmaceutical industry as medical advisor, she held senior management positions in different international contract research organizations and was responsible for operational, scientific, regulatory and business aspects of international clinical research projects from Phase I to Phase IV.
Since January 2003 she has her own pharmaceutical development and site management support consulting company. For 6 years she was also CEO of two investigative sites in London, UK, performing clinical trials in acute and chronic pain as well as musculo-skeletal diseases.
Dr. Klingmann is Chairman of the Board of the European Forum for Good Clinical Practice (EFGCP). On behalf of EFGCP she was Coordinator of the FP7-funded ICREL Project, Work Package Leader of the FP7-funded Patient Partner Project and at presently in her consultancy of the FP7-funded pediatric “LENA” Project. She is currently President of PharmaTrain Federation, the successor organization of the IMI Project PharmaTrain where she was Coordinator, and Work Package Leader of the IMI Project EUPATI, responsible for developing the EUPATI Network, the EUPATI National Platforms and the Ethics Panel.
Dr. Klingmann chairs the clinical research module of the post-graduate Master in the Regulatory Affairs course at the University of Bonn, Germany, co-founded and is lecturer in the Diploma Course in Clinical Trial Practices at the University of Basel, Switzerland, and is lecturer in the ECPM course at University of Basel and in the Pharmed course at Université Libre de Bruxelles, Belgium.
IFAPP Academy provides an online, continuing professional development course, Medical Affairs in Medicines Development, resulting in the Professional Certification, Certified Medicines Development (CMD).